Skip to main content

Table 3 The characteristics of primaquine group and non-primaquine group

From: Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure

 

Non primaquine (n = 31)

Primaquine (n = 18)

t/χ.2 value

P value

SMD

 

Before weighted

Male, n (%)

13 (42)

9 (50)

0.299

0.584

0.162

Age, yr ± SD

45.9 ± 18.7

54.3 ± 16.6

1.583

0.120

0.477

RID, n (%)

19 (61)

9 (50)

0.593

0.441

0.229

SS, n (%)

15 (48)

12 (67)

1.538

0.215

0.376

Steroid > 3 m, n (%)

20 (65)

13 (72)

0.308

0.579

0.166

IS, n (%)

25 (81)

15 (83)

0.000

1.000

0.070

p T/S, n (%)

7 (23)

1 (6)

1.331

0.249

0.505

TS, n (%)

21 (68)

14 (78)

0.562

0.453

0.227

WBC, × 10.9/L ± SD

9.0 ± 4.2

8.6 ± 4.1

0.375

0.710

0.111

LY, × 10.9/L ± SD

0.8 ± 0.6

0.6 ± 0.6

0.848

0.401

0.249

LDH, U/L ± SD

565.5 ± 205.0

637.4 ± 289.7

1.014

0.316

0.286

BDG, pg/ml ± SD

1210.9 ± 1015.3

786.5 ± 1010.7

 − 1.413

0.164

0.419

T/S to 2nd days, n (%)

7.2 ± 5.6

5.9 ± 5.1

0.000

1.000

0.233

Severe PCP, n (%)

23 (74)

13 (72)

0.000

1.000

0.045

CMV, n (%)

23 (74)

11 (61)

0.918

0.338

0.282

Bacteremia, n (%)

16 (52)

5 (28)

2.642

0.104

0.502

 

After weighted

Male, n (%)

12.7 (41)

6.8 (38)

0.054

0.816

0.070

Age, yr ± SD

47.8 ± 17.4

51.7 ± 14.8

0.807

0.424

0.243

RID, n (%)

17.1 (55)

9.2 (51)

0.082

0.774

0.084

SS, n (%)

16.6 (53)

8.2 (45)

0.293

0.588

0.162

Steroid > 3 m, n (%)

21.6 (70)

12.4 (69)

0.004

0.951

0.019

IS, n (%)

25.8 (83)

12.8 (71)

1.005

0.316

0.293

p T/S, n (%)

5.3 (17)

4.1 (23)

0.129

0.758

0.141

TS, n (%)

23.0 (74)

14.9 (83)

0.401

0.535

0.200

WBC, × 10.9/L ± SD

8.7 ± 4.5

9.5 ± 3.7

0.651

0.518

0.198

LY, × 10.9/L ± SD

0.7 ± 0.6

0.6 ± 0.6

 − 0.269

0.790

0.078

LDH, U/L ± SD

590.8 ± 200.2

623.5 ± 247.3

0.509

0.613

0.145

BDG, pg/ml ± SD

1066.3 ± 983.3

1056 ± 1204.7

0.036

0.971

0.009

T/S to 2nd days, n (%)

6.7 ± 5.2

5.7 ± 4.4

0.663

0.511

0.200

Severe PCP, n (%)

23.2 (75)

14.3 (79)

0.134

0.731

0.110

CMV infection, n (%)

22.8 (73)

13.5 (75)

0.015

0.903

0.037

Bacteremia, n (%)

13.8 (44)

9.7 (54)

0.428

0.513

0.196

  1. SMD standardized mean difference, RID rheumatic immune disease, SS sufficient steroid, IS immunosuppressant, p T/S preventive TMP/SMX, TS typical symptoms of simultaneous breathlessness at rest, persistent fever and cough, WBC white blood cell, LY lymphocyte, LDH lactate dehydrogenase, BDG (1–3)-beta-D-glucan, T/S to 2nd days TMP/SMX to second-line therapy days, PCP Pneumocystis jirovecii pneumonia, CMV Cytomegalovirus